Modality
Cell Therapy
MOA
Menini
Target
JAK2
Pathway
Amyloid
HCC
Development Pipeline
Preclinical
~Jul 2013
→ ~Oct 2014
Phase 1
~Jan 2015
→ ~Apr 2016
Phase 2
~Jul 2016
→ ~Oct 2017
Phase 3
~Jan 2018
→ ~Apr 2019
NDA/BLA
Jul 2019
→ Oct 2025
NDA/BLACurrent
NCT06803906
2,723 pts·HCC
2019-07→2025-10·Active
2,723 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-215mo agoPh3 Readout· HCC
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2025-10-21 · 5mo ago
HCC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06803906 | NDA/BLA | HCC | Active | 2723 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 | |
| IRO-8712 | Disc Medicine | Preclinical | JAK2 |